Seguir
Shenda Gu
Shenda Gu
QLSF Biotherapeutics
Dirección de correo verificada de qlsfbio.com
Título
Citado por
Citado por
Año
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
EA Collisson, A Sadanandam, P Olson, WJ Gibb, M Truitt, S Gu, J Cooc, ...
Nature medicine 17 (4), 500-503, 2011
12792011
A central role for RAF→ MEK→ ERK signaling in the genesis of pancreatic ductal adenocarcinoma
EA Collisson, CL Trejo, JM Silva, S Gu, JE Korkola, LM Heiser, ...
Cancer discovery 2 (8), 685-693, 2012
2822012
Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections
MS Draz, BA Fang, P Zhang, Z Hu, S Gu, KC Weng, JW Gray, FF Chen
Theranostics 4 (9), 872, 2014
2052014
Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer
W Ngamcherdtrakul, J Morry, S Gu, DJ Castro, SM Goodyear, ...
Advanced functional materials 25 (18), 2646-2659, 2015
1492015
The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer
Z Hu, G Huang, A Sadanandam, S Gu, ME Lenburg, M Pai, N Bayani, ...
Breast cancer research 12 (2), 1-15, 2010
1312010
Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis
J Morry, W Ngamcherdtrakul, S Gu, SM Goodyear, DJ Castro, MM Reda, ...
Biomaterials 66, 41-52, 2015
562015
Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform
J Morry, W Ngamcherdtrakul, S Gu, M Reda, DJ Castro, T Sangvanich, ...
Molecular cancer therapeutics 16 (4), 763-772, 2017
402017
Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery
W Ngamcherdtrakul, T Sangvanich, M Reda, S Gu, D Bejan, W Yantasee
International journal of nanomedicine 13, 4015, 2018
342018
Therapeutic siRNA for drug-resistant HER2-positive breast cancer
S Gu, Z Hu, W Ngamcherdtrakul, DJ Castro, J Morry, MM Reda, JW Gray, ...
Oncotarget 7 (12), 14727, 2016
302016
PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer
M Reda, W Ngamcherdtrakul, S Gu, DS Bejan, N Siriwon, JW Gray, ...
Cancer letters 467, 9-18, 2019
292019
Current development of targeted oligonucleotide-based cancer therapies: perspective on HER2-positive breast cancer treatment
W Ngamcherdtrakul, DJ Castro, S Gu, J Morry, M Reda, JW Gray, ...
Cancer treatment reviews 45, 19-29, 2016
202016
Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment
S Gu, W Ngamcherdtrakul, M Reda, Z Hu, JW Gray, W Yantasee
PloS one 13 (6), e0198141, 2018
132018
Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer
Z Hu, JH Mao, C Curtis, G Huang, S Gu, L Heiser, ME Lenburg, ...
Breast cancer research 18 (1), 1-12, 2016
102016
Lanthanide-Loaded Nanoparticles as Potential Fluorescent and Mass Probes for High-Content Protein Analysis
W Ngamcherdtrakul, T Sangvanich, S Goodyear, M Reda, S Gu, ...
Bioengineering 6 (1), 23, 2019
52019
Abstract 2020: A Systems Analysis of Mitotic Apparatus Inhibitors Defines a Response Network for Breast Cancer.
Z Hu, J Mao, G Huang, W Kuo, M Lenburg, S Ziyad, J Korkola, N Bayani, ...
Cancer Research 69 (24 Supplement), 2020-2020, 2009
12009
Abstract 5572: Small molecular inhibitor of centromere-associated protein E (CENP-E), GSK923295A inhibits cell growth in breast cancer cells
Z Hu, W Kuo, D Das, S Ziyad, S Gu, S Bhattacharya, A Wyrobek, N Wang, ...
Cancer Research 69 (9 Supplement), 5572-5572, 2009
12009
4th International Conference on Nanotek & Expo
M Reda, W Yantasee, W Ngamcherdtrakul, S Gu, J Morry, S Goodyear, ...
2014
P5. EXPERIMENTAL THERAPEUTICS
S Gu, S Goodyear, W Ngamcherdtrakul, J Morry, T Sangvanich, D Castro, ...
2014
Abstract LB-208: Small interfering RNA library screen to identify therapeutic transcription factor.
Z Hu, S Gu, J Gray, J Rantala
Cancer Research 73 (8 Supplement), LB-208-LB-208, 2013
2013
Abstract LB-258: Developing therapeutic siRNA against HER2 in breast cancer cells
Z Hu, S Gu, J Rantala, W Ngamcherdtrakul, W Yantasee, JW Gray
Cancer Research 72 (8 Supplement), LB-258-LB-258, 2012
2012
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20